Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BriaCell (Nasdaq: BCTX) Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer.
PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a clinical supply agreement with BeiGene, Ltd. (NASDAQ: BGNE) (“BeiGene”) to evaluate the safety and efficacy of Bria-OTS™, BriaCell’s next generation immunotherapy, in combination with BeiGene's anti-PD-1 antibody, tislelizumab, for the treatment of advanced heavily pretreated metastatic breast cancer.
“We are extremely excited about partnering with BeiGene on this novel immunotherapy approach with planned expansion to prostate and other cancers,” stated Dr. William V. Williams, BriaCell’s President & CEO. “This agreement marks another positive milestone for BriaCell in our commitment to transform cancer care.”
“The Bria-OTS™ platform capitalizes on our success with Bria-IMT™, which has shown clinical benefit after check point inhibitors (CPIs) resistance,” stated Dr. Del Priore, BriaCell’s Chief Medical Officer. “In our randomized Phase 2 and other trials of Bria-IMT™, BriaCell immunotherapy has shown survival and clinical benefit in patients with central nervous system (CNS) metastases and after progression on antibody drug conjugates (ADCs). The Bria-OTS™ platform is the next generation off-the-shelf therapy with enhanced potency. There is rationale to predict that combining Bria-OTS™ with tislelizumab may impart additional benefit in this refractory patient population.”
The limited access Phase 1/2 clinical trial will initially evaluate the safety and efficacy of Bria-OTS™ alone in breast cancer and later in combination with tislelizumab. BriaCell also plans to evaluate Bria-OTS™ in prostate and other cancers.
BriaCell (Nasdaq: BCTX) Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer.
PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a clinical supply agreement with BeiGene, Ltd. (NASDAQ: BGNE) (“BeiGene”) to evaluate the safety and efficacy of Bria-OTS™, BriaCell’s next generation immunotherapy, in combination with BeiGene's anti-PD-1 antibody, tislelizumab, for the treatment of advanced heavily pretreated metastatic breast cancer.
“We are extremely excited about partnering with BeiGene on this novel immunotherapy approach with planned expansion to prostate and other cancers,” stated Dr. William V. Williams, BriaCell’s President & CEO. “This agreement marks another positive milestone for BriaCell in our commitment to transform cancer care.”
“The Bria-OTS™ platform capitalizes on our success with Bria-IMT™, which has shown clinical benefit after check point inhibitors (CPIs) resistance,” stated Dr. Del Priore, BriaCell’s Chief Medical Officer. “In our randomized Phase 2 and other trials of Bria-IMT™, BriaCell immunotherapy has shown survival and clinical benefit in patients with central nervous system (CNS) metastases and after progression on antibody drug conjugates (ADCs). The Bria-OTS™ platform is the next generation off-the-shelf therapy with enhanced potency. There is rationale to predict that combining Bria-OTS™ with tislelizumab may impart additional benefit in this refractory patient population.”
The limited access Phase 1/2 clinical trial will initially evaluate the safety and efficacy of Bria-OTS™ alone in breast cancer and later in combination with tislelizumab. BriaCell also plans to evaluate Bria-OTS™ in prostate and other cancers.
BriaCell (Nasdaq: BCTX) Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer.
PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a clinical supply agreement with BeiGene, Ltd. (NASDAQ: BGNE) (“BeiGene”) to evaluate the safety and efficacy of Bria-OTS™, BriaCell’s next generation immunotherapy, in combination with BeiGene's anti-PD-1 antibody, tislelizumab, for the treatment of advanced heavily pretreated metastatic breast cancer.
“We are extremely excited about partnering with BeiGene on this novel immunotherapy approach with planned expansion to prostate and other cancers,” stated Dr. William V. Williams, BriaCell’s President & CEO. “This agreement marks another positive milestone for BriaCell in our commitment to transform cancer care.”
“The Bria-OTS™ platform capitalizes on our success with Bria-IMT™, which has shown clinical benefit after check point inhibitors (CPIs) resistance,” stated Dr. Del Priore, BriaCell’s Chief Medical Officer. “In our randomized Phase 2 and other trials of Bria-IMT™, BriaCell immunotherapy has shown survival and clinical benefit in patients with central nervous system (CNS) metastases and after progression on antibody drug conjugates (ADCs). The Bria-OTS™ platform is the next generation off-the-shelf therapy with enhanced potency. There is rationale to predict that combining Bria-OTS™ with tislelizumab may impart additional benefit in this refractory patient population.”
The limited access Phase 1/2 clinical trial will initially evaluate the safety and efficacy of Bria-OTS™ alone in breast cancer and later in combination with tislelizumab. BriaCell also plans to evaluate Bria-OTS™ in prostate and other cancers.
BriaCell to showcase groundbreaking findings at ASCO 2024.
Details here: https://www.globenewswire.com/.../BriaCell-Announces-Oral...
Dr. Saranya Chumsri from Mayo Clinic leads an oral presentation on the promising Bria-IMT™ in metastatic breast cancer. Additionally, two posters will feature insights into ongoing clinical studies.
#ASCO2024 #CancerResearch #stockstowatch $BCTX
BriaCell to showcase groundbreaking findings at ASCO 2024.
Details here: https://www.globenewswire.com/.../BriaCell-Announces-Oral...
Dr. Saranya Chumsri from Mayo Clinic leads an oral presentation on the promising Bria-IMT™ in metastatic breast cancer. Additionally, two posters will feature insights into ongoing clinical studies.
#ASCO2024 #CancerResearch #stockstowatch $BCTX
BriaCell to showcase groundbreaking findings at ASCO 2024.
Details here: https://www.globenewswire.com/.../BriaCell-Announces-Oral...
Dr. Saranya Chumsri from Mayo Clinic leads an oral presentation on the promising Bria-IMT™ in metastatic breast cancer. Additionally, two posters will feature insights into ongoing clinical studies.
#ASCO2024 #CancerResearch #stockstowatch $BCTX
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
https://finance.yahoo.com/news/briacell-announces-strong-clinical-data-130000153.html
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study
Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapy
Notable responder had failed 4 prior therapies including ADC therapy with metastatic liver tumor “no longer observed” following BriaCell treatment
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
https://finance.yahoo.com/news/briacell-announces-strong-clinical-data-130000153.html
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
https://finance.yahoo.com/news/briacell-announces-strong-clinical-data-130000153.html
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
https://finance.yahoo.com/news/briacell-announces-strong-clinical-data-130000153.html
BriaCell Therapeutics Corp. (Nasdaq: BCTX) Up 10% on News
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles
Stock up 10% so far on this news.
Read more about it https://bit.ly/3RNwgq1
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) Up 10%
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles
Stock up 10% so far on this news.
Read more about it https://bit.ly/3RNwgq1
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles
Stock up 10% so far on this news.
Read more about it https://bit.ly/3RNwgq1
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
Stock up 10% so far on this news.
Endexx® Corporation (OTCQB: EDXC) Featured on SmallCapVoice.com HYLA Targets 300% Growth Rate Per Year
Exclusive interview with Todd Davis, CEO of Endexx Corporation, and Nick Mehdi, CEO of HYLA! Exciting discussions about the groundbreaking strides HYLA has made for OTCQB: EDXC
Tune in for insights into future plans
Endexx® Corporation (OTCQB: EDXC) HYLA Targets 300% Growth Rate Per Year
Exclusive interview with Todd Davis, CEO of Endexx Corporation, and Nick Mehdi, CEO of HYLA! Exciting discussions about the groundbreaking strides HYLA has made for OTCQB: EDXC
Tune in for insights into future plans
EDXC HYLA Targets 300% Growth Rate Per Year Endexx® Corporation (OTCQB: EDXC) Featured on SmallCapVoice.com
Exclusive interview with Todd Davis, CEO of Endexx Corporation, and Nick Mehdi, CEO of HYLA! Exciting discussions about the groundbreaking strides HYLA has made for OTCQB: EDXC
Tune in for insights into future plans
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) News!
🎗October is Breast Cancer Awareness 🎗
BriaCell is leading the fight with recent study showing survival rate of 13.5 months, offering hope in advanced metastatic breast cancer.
Find out more about the month and BriaCells progress here: https://www.globenewswire.com/news-release/2023/10/20/2764046/0/en/October-is-Breast-Cancer-Awareness-Month-BriaCell-is-Leading-the-Fight-with-its-Innovative-Technology.html
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) News!
🎗October is Breast Cancer Awareness 🎗
BriaCell is leading the fight with recent study showing survival rate of 13.5 months, offering hope in advanced metastatic breast cancer.
Find out more about the month and BriaCells progress here: https://www.globenewswire.com/news-release/2023/10/20/2764046/0/en/October-is-Breast-Cancer-Awareness-Month-BriaCell-is-Leading-the-Fight-with-its-Innovative-Technology.html
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) News!
🎗October is Breast Cancer Awareness 🎗
BriaCell is leading the fight with recent study showing survival rate of 13.5 months, offering hope in advanced metastatic breast cancer.
Find out more about the month and BriaCells progress here: https://www.globenewswire.com/news-release/2023/10/20/2764046/0/en/October-is-Breast-Cancer-Awareness-Month-BriaCell-is-Leading-the-Fight-with-its-Innovative-Technology.html
(Nasdaq: BCTX) (TSX: BCT) BriaCell teams up with New York Cancer & Blood Specialists for Phase 3 study of Bria-IMT™ in advanced breast cancer. Together, pioneering new paths in cancer care at one of the nation’s leading cancer centers.
https://globenewswire.com/news-release/2023/10/04/2754618/0/en/BriaCell-Partners-with-New-York-Cancer-Blood-Specialists-NYCBS-for-Pivotal-Phase-3-Study-of-Bria-IMT-in-Advanced-Breast-Cancer.html
#Phase3Study #CancerCare
(Nasdaq: BCTX) (TSX: BCT) BriaCell teams up with New York Cancer & Blood Specialists for Phase 3 study of Bria-IMT™ in advanced breast cancer. Together, pioneering new paths in cancer care at one of the nation’s leading cancer centers.
https://globenewswire.com/news-release/2023/10/04/2754618/0/en/BriaCell-Partners-with-New-York-Cancer-Blood-Specialists-NYCBS-for-Pivotal-Phase-3-Study-of-Bria-IMT-in-Advanced-Breast-Cancer.html
(Nasdaq: BCTX) (TSX: BCT) BriaCell teams up with New York Cancer & Blood Specialists for Phase 3 study of Bria-IMT™ in advanced breast cancer. Together, pioneering new paths in cancer care at one of the nation’s leading cancer centers.
https://globenewswire.com/news-release/2023/10/04/2754618/0/en/BriaCell-Partners-with-New-York-Cancer-Blood-Specialists-NYCBS-for-Pivotal-Phase-3-Study-of-Bria-IMT-in-Advanced-Breast-Cancer.html
#Phase3Study #CancerCare
News Alert: BriaCell (Nasdaq: BCTX) (TSX: BCT) Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
-Median Survival: 13.5 months (vs. 6.7-9.8)
-21 of 29 terminal patients treated since 2022 are alive
-No toxicities reported
(Nasdaq: BCTX) becoming a ray of hope in the toughest fight. #CancerBreakthrough
https://finance.yahoo.com/news/briacell-reports-benchmark-beating-patient-110000318.html
News Alert: BriaCell (Nasdaq: BCTX) (TSX: BCT) Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
-21 of 29 terminal patients treated since 2022 are alive
https://finance.yahoo.com/news/briacell-reports-benchmark-beating-patient-110000318.html
News Alert: BriaCell (Nasdaq: BCTX) (TSX: BCT) Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
-21 of 29 terminal patients treated since 2022 are alive
https://finance.yahoo.com/news/briacell-reports-benchmark-beating-patient-110000318.html
BCTX Big News Today
FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and improve patients’ lives, announces that it has received approval from FDA on its pivotal registrational study design for Bria-IMT™ in combination with a checkpoint inhibitor in advanced metastatic breast cancer.
FDA has approved the study design, the primary and secondary endpoints, and patient population in BriaCell’s upcoming pivotal registration clinical study. The study will include advanced metastatic breast cancer patients who have exhausted all other treatment options.
The trial will be a randomized, open-label study comparing the Bria-IMT™ combination regimen with an immune check point inhibitor in one arm with treatment of physicians’ choice in another arm in advanced metastatic breast cancer. A third smaller arm with the Bria-IMT™ regimen alone will be included in the study to address FDA’s combination drug assessment requirements. Upon achieving statistically significant milestones, BriaCell may apply for full approval of the Bria-IMT™ combination regimen following the Biologics Licensing Application (BLA) filing process.
“FDA approval of our study design represents a major milestone towards our goal of making a huge impact in the lives of advanced metastatic breast cancer patients who have failed currently approved therapies,” stated Dr. William V. Williams, BriaCell’s President and CEO.
“We are extremely grateful that the FDA Office of Oncologic Diseases has approved our strategy and has provided us with a route to accelerate the development of our novel immunotherapy in this difficult-to-treat patient population. A successful study may significantly transform the approach to treat advanced breast cancer,” added Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We are working closely with FDA to further accelerate the development of our lead candidate and eventual market authorization.”
Patient recruitment and dosing will commence in summer 2023.
BCTX Big News Today
FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and improve patients’ lives, announces that it has received approval from FDA on its pivotal registrational study design for Bria-IMT™ in combination with a checkpoint inhibitor in advanced metastatic breast cancer.
FDA has approved the study design, the primary and secondary endpoints, and patient population in BriaCell’s upcoming pivotal registration clinical study. The study will include advanced metastatic breast cancer patients who have exhausted all other treatment options.
The trial will be a randomized, open-label study comparing the Bria-IMT™ combination regimen with an immune check point inhibitor in one arm with treatment of physicians’ choice in another arm in advanced metastatic breast cancer. A third smaller arm with the Bria-IMT™ regimen alone will be included in the study to address FDA’s combination drug assessment requirements. Upon achieving statistically significant milestones, BriaCell may apply for full approval of the Bria-IMT™ combination regimen following the Biologics Licensing Application (BLA) filing process.
“FDA approval of our study design represents a major milestone towards our goal of making a huge impact in the lives of advanced metastatic breast cancer patients who have failed currently approved therapies,” stated Dr. William V. Williams, BriaCell’s President and CEO.
“We are extremely grateful that the FDA Office of Oncologic Diseases has approved our strategy and has provided us with a route to accelerate the development of our novel immunotherapy in this difficult-to-treat patient population. A successful study may significantly transform the approach to treat advanced breast cancer,” added Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We are working closely with FDA to further accelerate the development of our lead candidate and eventual market authorization.”
Patient recruitment and dosing will commence in summer 2023.
BCTX Big News Today
FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and improve patients’ lives, announces that it has received approval from FDA on its pivotal registrational study design for Bria-IMT™ in combination with a checkpoint inhibitor in advanced metastatic breast cancer.
FDA has approved the study design, the primary and secondary endpoints, and patient population in BriaCell’s upcoming pivotal registration clinical study. The study will include advanced metastatic breast cancer patients who have exhausted all other treatment options.
The trial will be a randomized, open-label study comparing the Bria-IMT™ combination regimen with an immune check point inhibitor in one arm with treatment of physicians’ choice in another arm in advanced metastatic breast cancer. A third smaller arm with the Bria-IMT™ regimen alone will be included in the study to address FDA’s combination drug assessment requirements. Upon achieving statistically significant milestones, BriaCell may apply for full approval of the Bria-IMT™ combination regimen following the Biologics Licensing Application (BLA) filing process.
“FDA approval of our study design represents a major milestone towards our goal of making a huge impact in the lives of advanced metastatic breast cancer patients who have failed currently approved therapies,” stated Dr. William V. Williams, BriaCell’s President and CEO.
“We are extremely grateful that the FDA Office of Oncologic Diseases has approved our strategy and has provided us with a route to accelerate the development of our novel immunotherapy in this difficult-to-treat patient population. A successful study may significantly transform the approach to treat advanced breast cancer,” added Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We are working closely with FDA to further accelerate the development of our lead candidate and eventual market authorization.”
Patient recruitment and dosing will commence in summer 2023.
Don't miss our latest interview with Bruce Rintoul, a key Member of the Board of Directors at SusGlobal Energy Corp (OTCQB: SNRG).
Listen to the full interview here: https://finance.yahoo.com/news/susglobal-energy-corp-director-former-120000549.html
#Stocks #OTCMarkets #OTC
Don't miss our latest interview with Bruce Rintoul, a key Member of the Board of Directors at SusGlobal Energy Corp (OTCQB: SNRG).
Listen to the full interview here: https://finance.yahoo.com/news/susglobal-energy-corp-director-former-120000549.html
#Stocks #OTCMarkets #OTC
Don't miss our latest interview with Bruce Rintoul, a key Member of the Board of Directors at SusGlobal Energy Corp (OTCQB: SNRG).
Listen to the full interview here: https://www.accesswire.com/.../SusGlobal-Energy-Corp...
#Stocks #OTCMarkets #OTC
$BCTX $15 Price Target
Zacks Small-Cap Research just released a new report on BriaCell Therapeutics Corp. (Nasdaq: BCTX) with a $15 price target.
Read the full report here: https://scr.zacks.com/.../BCTX-Posters.../default.aspx
#Stocks #StocksToWatch #StockMarket
$BCTX $15 Price Target
Zacks Small-Cap Research just released a new report on BriaCell Therapeutics Corp. (Nasdaq: BCTX) with a $15 price target.
Read the full report here: https://scr.zacks.com/.../BCTX-Posters.../default.aspx
#Stocks #StocksToWatch #StockMarket
$BCTX $15 Price Target
Zacks Small-Cap Research just released a new report on BriaCell Therapeutics Corp. (Nasdaq: BCTX) with a $15 price target.
Read the full report here: https://scr.zacks.com/.../BCTX-Posters.../default.aspx
#Stocks #StocksToWatch #StockMarket
$BCTX $15 Price Target
Zacks Small-Cap Research just released a new report on BriaCell Therapeutics Corp. (Nasdaq: BCTX) with a $15 price target.
Read the full report here: https://scr.zacks.com/.../BCTX-Posters.../default.aspx
#Stocks #StocksToWatch #StockMarket
$SNRG SusGlobal Energy Corp. Reports Fourth Quarter and Full Year 2022 Financial Results
Great news for shareholders of SusGlobal Energy Corp (OTCQB: SNRG)!
The Company’s Fourth Quarter and Full Year 2022 Financial Results are in.
Check out their press release here: https://finance.yahoo.com/news/susglobal-energy-corp-reports-fourth-123000829.html
#Stocks #StocksInFocus #OTC
$SNRG SusGlobal Energy Corp. Reports Fourth Quarter and Full Year 2022 Financial Results
Great news for shareholders of SusGlobal Energy Corp (OTCQB: SNRG)!
The Company’s Fourth Quarter and Full Year 2022 Financial Results are in.
Check out their press release here: https://finance.yahoo.com/news/susglobal-energy-corp-reports-fourth-123000829.html
#Stocks #StocksInFocus #OTC
$BCTX $25 Price Target and Stock is Breaking Out
Big news for BriaCell (Nasdaq: BCTX) investors: H.C. Wainwright & Co. issues a buy rating and a $25 price target for this innovative #biotech company.
Is $BCTX on your watchlist?
#Stocks #StockMarket
$BCTX New Buy Rating with $25 price target from H.C. Wainwright!